<VariationArchive VariationID="1362479" VariationName="NC_000001.10:g.(?_17345376)_(17359650_?)del" VariationType="Deletion" Accession="VCV001362479" Version="14" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-07-15" DateCreated="2022-03-28" MostRecentSubmission="2024-06-09">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1373227" VariationID="1362479">
      <GeneList>
        <Gene Symbol="SDHB" FullName="succinate dehydrogenase complex iron sulfur subunit B" GeneID="6390" HGNC_ID="HGNC:10681" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>1p36.13</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="17018722" stop="17054032" display_start="17018722" display_stop="17054032" Strand="-" />
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="1" Accession="NW_025791756.1" start="1433916" stop="1469227" display_start="1433916" display_stop="1469227" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" start="17345216" stop="17380664" display_start="17345216" display_stop="17380664" Strand="-" />
          </Location>
          <OMIM>185470</OMIM>
          <Haploinsufficiency last_evaluated="2020-07-22" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=SDHB">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2020-07-22" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=SDHB">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NC_000001.10:g.(?_17345376)_(17359650_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>1p36.13</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" innerStart="17345376" innerStop="17359650" display_start="17345376" display_stop="17359650" variantLength="14275" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000001.10" sequenceAccession="NC_000001" sequenceVersion="10" change="g.(?_17345376)_(17359650_?)del" Assembly="GRCh37">
            <Expression>NC_000001.10:g.(?_17345376)_(17359650_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000001.10:g.(?_17345376)_(17359650_?)del AND multiple conditions" Accession="RCV001932317" Version="8">
        <ClassifiedConditionList TraitSetID="23696">
          <ClassifiedCondition DB="MedGen" ID="C0238198">Gastrointestinal stromal tumor</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1861848">Paragangliomas 4</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0031511">Pheochromocytoma</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-10-27" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-10-27" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2022-03-28" MostRecentSubmission="2024-06-09">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">17652212</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">19029228</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22517554</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24977658</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="23696" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="3267" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">CAROTID BODY TUMORS AND MULTIPLE EXTRAADRENAL PHEOCHROMOCYTOMAS</ElementValue>
                <XRef Type="MIM" ID="115310" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Paragangliomas 4</ElementValue>
                <XRef ID="Paragangliomas+4/5581" DB="Genetic Alliance" />
                <XRef ID="MONDO:0007273" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">SDHB-Related Hereditary Paraganglioma-Pheochromocytoma Syndrome (Paragangliomas 4)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">PHEOCHROMOCYTOMA/PARAGANGLIOMA SYNDROME 4</ElementValue>
                <XRef Type="MIM" ID="115310" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0021" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0009" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0016" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0006" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0005" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0019" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0023" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0007" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0017" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0008" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0003" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0001" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0018" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0002" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0004" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0010" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Pheochromocytoma, extraadrenal and cervical paraganglioma</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Paragangliomas, hereditary extraadrenal</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Pheochromocytoma, familial extraadrenal</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Paraganglioma, familial malignant</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">PPGL4</ElementValue>
                <XRef Type="MIM" ID="115310" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">PGL4</ElementValue>
                <XRef Type="MIM" ID="115310" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10546" />
                <XRef ID="10546" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Hereditary paraganglioma-pheochromocytoma (PGL/PCC) syndromes are characterized by paragangliomas (tumors that arise from neuroendocrine tissues distributed along the paravertebral axis from the base of the skull to the pelvis) and pheochromocytomas (paragangliomas that are confined to the adrenal medulla). Sympathetic paragangliomas cause catecholamine excess; parasympathetic paragangliomas are most often nonsecretory. Extra-adrenal parasympathetic paragangliomas are located predominantly in the skull base and neck (referred to as head and neck PGL [HNPGL]) and sometimes in the upper mediastinum; approximately 95% of such tumors are nonsecretory. In contrast, sympathetic extra-adrenal paragangliomas are generally confined to the lower mediastinum, abdomen, and pelvis, and are typically secretory. Pheochromocytomas, which arise from the adrenal medulla, typically lead to catecholamine excess. Symptoms of PGL/PCC result from either mass effects or catecholamine hypersecretion (e.g., sustained or paroxysmal elevations in blood pressure, headache, episodic profuse sweating, forceful palpitations, pallor, and apprehension or anxiety). The risk for developing metastatic disease is greater for extra-adrenal sympathetic paragangliomas than for pheochromocytomas.</Attribute>
                <XRef ID="NBK1548" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301715</ID>
                <ID Source="BookShelf">NBK1548</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2010">
                <ID Source="PubMed">20065170</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2009">
                <ID Source="pmc">2668639</ID>
              </Citation>
              <Citation Type="review">
                <ID Source="PubMed">20816580</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="general" Abbrev="ES, 2014">
                <ID Source="PubMed">24893135</ID>
              </Citation>
              <Citation Type="general" Abbrev="NANETS, 2010">
                <ID Source="PubMed">20664475</ID>
                <ID Source="pmc">3419007</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <Citation Type="general" Abbrev="KCRNC, 2013">
                <ID Source="PubMed">24319509</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2015">
                <ID Source="PubMed">26324357</ID>
              </Citation>
              <Citation Type="general" Abbrev="NANETS, 2021">
                <ID Source="PubMed">33939658</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Neuroendocrine and Adrenal Tumors, 2023</CitationText>
              </Citation>
              <XRef ID="29072" DB="Orphanet" />
              <XRef ID="C1861848" DB="MedGen" />
              <XRef ID="MONDO:0007273" DB="MONDO" />
              <XRef Type="MIM" ID="115310" DB="OMIM" />
            </Trait>
            <Trait ID="3796" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Pheochromocytoma</ElementValue>
                <XRef ID="Pheochromocytoma/5718" DB="Genetic Alliance" />
                <XRef ID="HP:0002666" DB="Human Phenotype Ontology" />
                <XRef ID="MONDO:0008233" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Chromaffinoma</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Chromaffin paraganglioma</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Chromaffin tumor</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Medullary paraganglioma</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Chromaffin cell tumor</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="keyword">KIF1B-Related Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">MAX-Related Susceptibility to Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">VHL-Related Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">TMEM127-Related Susceptibility to Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">RET-Related Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Hereditary paraganglioma-pheochromocytoma (PGL/PCC) syndromes are characterized by paragangliomas (tumors that arise from neuroendocrine tissues distributed along the paravertebral axis from the base of the skull to the pelvis) and pheochromocytomas (paragangliomas that are confined to the adrenal medulla). Sympathetic paragangliomas cause catecholamine excess; parasympathetic paragangliomas are most often nonsecretory. Extra-adrenal parasympathetic paragangliomas are located predominantly in the skull base and neck (referred to as head and neck PGL [HNPGL]) and sometimes in the upper mediastinum; approximately 95% of such tumors are nonsecretory. In contrast, sympathetic extra-adrenal paragangliomas are generally confined to the lower mediastinum, abdomen, and pelvis, and are typically secretory. Pheochromocytomas, which arise from the adrenal medulla, typically lead to catecholamine excess. Symptoms of PGL/PCC result from either mass effects or catecholamine hypersecretion (e.g., sustained or paroxysmal elevations in blood pressure, headache, episodic profuse sweating, forceful palpitations, pallor, and apprehension or anxiety). The risk for developing metastatic disease is greater for extra-adrenal sympathetic paragangliomas than for pheochromocytomas.</Attribute>
                <XRef ID="NBK1548" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">SDHB-Related Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">SDHD-Related Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">MAX-Related Hereditary Paraganglioma-Pheochromocytoma Syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="15105" />
                <XRef ID="15105" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301715</ID>
                <ID Source="BookShelf">NBK1548</ID>
              </Citation>
              <Citation Type="general" Abbrev="ES, 2014">
                <ID Source="PubMed">24893135</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2014">
                <ID Source="PubMed">24493721</ID>
              </Citation>
              <Citation Type="general" Abbrev="NANETS, 2010">
                <ID Source="PubMed">20664475</ID>
                <ID Source="pmc">3419007</ID>
              </Citation>
              <Citation Type="general" Abbrev="KCRNC, 2013">
                <ID Source="PubMed">24319509</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Endocrine and Neuroendocrine Neoplasia genetics">
                <ID Source="PubMed">26389271</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="general" Abbrev="NANETS, 2021">
                <ID Source="PubMed">33939658</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Neuroendocrine and Adrenal Tumors, 2023</CitationText>
              </Citation>
              <XRef ID="29072" DB="Orphanet" />
              <XRef ID="C0031511" DB="MedGen" />
              <XRef ID="MONDO:0008233" DB="MONDO" />
              <XRef Type="MIM" ID="171300" DB="OMIM" />
              <XRef Type="primary" ID="HP:0002666" DB="Human Phenotype Ontology" />
            </Trait>
            <Trait ID="2160" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Gastrointestinal stroma tumor</ElementValue>
                <XRef ID="HP:0100723" DB="Human Phenotype Ontology" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Gastrointestinal stromal tumor</ElementValue>
                <XRef ID="Gastrointestinal+Stromal+Tumors/2997" DB="Genetic Alliance" />
                <XRef ID="MONDO:0011719" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gastrointestinal Stromal Sarcoma</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gastrointestinal stromal tumor, somatic</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">GIST</ElementValue>
                <XRef Type="MIM" ID="606764" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">KIT</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="8598" />
                <XRef ID="8598" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <Citation Type="general" Abbrev="UK NEQAS, 2012">
                <ID Source="PubMed">22685257</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <Citation Type="general" Abbrev="EGTM, 2014">
                <ID Source="PubMed">23852704</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Gastrointestinal Stromal Tumors, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2024">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Soft Tissue Sarcoma, 2024</CitationText>
              </Citation>
              <XRef ID="44890" DB="Orphanet" />
              <XRef ID="C0238198" DB="MedGen" />
              <XRef ID="D046152" DB="MeSH" />
              <XRef ID="MONDO:0011719" DB="MONDO" />
              <XRef Type="MIM" ID="606764" DB="OMIM" />
              <XRef Type="primary" ID="HP:0100723" DB="Human Phenotype Ontology" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="4142559" SubmissionDate="2024-06-04" DateLastUpdated="2024-06-09" DateCreated="2022-03-28">
        <ClinVarSubmissionID localKey="NM_003000.2_1_Deletion (exons 3-8)|MedGen:C0238198;C1861848;C0031511" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002121624" DateUpdated="2024-06-09" DateCreated="2022-03-28" Type="SCV" Version="4" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-10-27">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">17652212</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">19029228</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22517554</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24977658</ID>
          </Citation>
          <Comment>This variant is a gross deletion of the genomic region encompassing exon(s) 3-8 of the SDHB gene, which includes the termination codon. This deletion extends beyond the assayed region for this gene and therefore may encompass additional genes. While this deletion is not anticipated to lead to nonsense mediated decay, it is expected to alter mRNA translation or result in a truncated protein product. This variant has not been reported in the literature in individuals affected with SDHB-related conditions. The region of the SDHB gene that includes exon(s) 7 has been determined to be clinically significant (PMID: 17652212, 19029228, 22517554, 24977658). Therefore, deletions that encompass that region are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SDHB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000001.10:g.(?_17345376)_(17359650_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease" multipleConditionExplanation="Uncertain">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0238198" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1861848" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0031511" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11173117</SubmissionName>
          <SubmissionName>SUB12699154</SubmissionName>
          <SubmissionName>SUB14505679</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="4142559" TraitType="Disease" MappingType="XRef" MappingValue="C0031511" MappingRef="MedGen">
        <MedGen CUI="C0031511" Name="Pheochromocytoma" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4142559" TraitType="Disease" MappingType="XRef" MappingValue="C1861848" MappingRef="MedGen">
        <MedGen CUI="C1861848" Name="Paragangliomas 4" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4142559" TraitType="Disease" MappingType="XRef" MappingValue="C0238198" MappingRef="MedGen">
        <MedGen CUI="C0238198" Name="Gastrointestinal stromal tumor" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

